KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Net Income (2017 - 2025)

Historic Net Income for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $18.1 million.

  • Amneal Pharmaceuticals' Net Income rose 5422.3% to $18.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $57.6 million, marking a year-over-year increase of 13929.75%. This contributed to the annual value of -$73.9 million for FY2024, which is 5155.42% down from last year.
  • Latest data reveals that Amneal Pharmaceuticals reported Net Income of $18.1 million as of Q3 2025, which was up 5422.3% from $35.6 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Net Income registered a high of $35.6 million during Q2 2025, and its lowest value of -$240.1 million during Q2 2022.
  • Its 5-year average for Net Income is -$14.7 million, with a median of -$2.4 million in 2022.
  • Over the last 5 years, Amneal Pharmaceuticals' Net Income had its largest YoY gain of 113541.32% in 2023, and its largest YoY loss of 149508.11% in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' Net Income stood at -$20.4 million in 2021, then soared by 71.33% to -$5.9 million in 2022, then plummeted by 1495.08% to -$93.4 million in 2023, then surged by 77.75% to -$20.8 million in 2024, then soared by 187.26% to $18.1 million in 2025.
  • Its last three reported values are $18.1 million in Q3 2025, $35.6 million for Q2 2025, and $24.6 million during Q1 2025.